Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $11.0 million.

  • Harmony Biosciences Holdings' Share-based Compensation fell 418.41% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 798.45%. This contributed to the annual value of $42.6 million for FY2024, which is 3437.0% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Share-based Compensation stood at $11.0 million for Q3 2025, which was down 418.41% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Share-based Compensation ranged from a high of $12.5 million in Q1 2025 and a low of $3.3 million during Q1 2021
  • Its 5-year average for Share-based Compensation is $8.0 million, with a median of $7.8 million in 2023.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Share-based Compensation soared by 72581.34% in 2021, and later crashed by 418.41% in 2025.
  • Quarter analysis of 5 years shows Harmony Biosciences Holdings' Share-based Compensation stood at $4.4 million in 2021, then soared by 58.32% to $6.9 million in 2022, then grew by 27.73% to $8.9 million in 2023, then increased by 13.64% to $10.1 million in 2024, then grew by 8.91% to $11.0 million in 2025.
  • Its Share-based Compensation was $11.0 million in Q3 2025, compared to $11.5 million in Q2 2025 and $12.5 million in Q1 2025.